Defective Boston Scientific Taxus Drug-Eluting Stents Lead To FDA Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Boston Scientific’s third warning letter notes eight quarantined units of the stent were distributed to hospitals in January. The company has yet to show that it has made “real changes” to its quality system, according to FDA's Aug. 10 letter.